These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 12515379

  • 1. Bone disease in uremic patients: advances in PTH suppression.
    Brancaccio D, Cozzolino M, Gorio A, Di Giulio AM, Gallieni M.
    J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 4. Management of secondary hyperparathyroidism.
    Cunningham J.
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S35-40. PubMed ID: 16109140
    [Abstract] [Full Text] [Related]

  • 5. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005 Aug; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

  • 6. Vitamin D3 polyunsaturated side-chain analogues (EB1089, GS1590) and the 20-epi-vitamin D3 analogue CB1393 suppress parathyroid hormone secretion and mRNA level in bovine parathyroid cells.
    Segersten U, Holm PK, Binderup L, Akerström G, Hellman P, Westin G.
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):289-94. PubMed ID: 15120422
    [Abstract] [Full Text] [Related]

  • 7. Parathyroid growth and suppression in renal failure.
    Lewin E, Huan J, Olgaard K.
    Semin Dial; 2006 Mar; 19(3):238-45. PubMed ID: 16689976
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR, Tian J, Goltzman D.
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [Abstract] [Full Text] [Related]

  • 9. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M.
    J Nephrol; 2007 Mar; 20(1):3-9. PubMed ID: 17347966
    [Abstract] [Full Text] [Related]

  • 10. [Renal failure and vitamin D].
    Brown AJ, Dusso AS, Slatopolsky E.
    Clin Calcium; 2002 Jun; 12(6):711-23. PubMed ID: 15775356
    [Abstract] [Full Text] [Related]

  • 11. Vitamin D physiology.
    Lips P.
    Prog Biophys Mol Biol; 2006 Sep; 92(1):4-8. PubMed ID: 16563471
    [Abstract] [Full Text] [Related]

  • 12. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 13. New therapies for uremic secondary hyperparathyroidism.
    Torres PU, Prié D, Beck L, Friedlander G.
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [Abstract] [Full Text] [Related]

  • 14. Strategies to minimize bone disease in renal failure.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
    Brown AJ, Slatopolsky E.
    Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
    [Abstract] [Full Text] [Related]

  • 16. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
    Brown AJ.
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J.
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G.
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [Abstract] [Full Text] [Related]

  • 19. The role of phosphorus in the genesis of azotemic osteodystrophy.
    Somerville PJ, Kaye M.
    Prog Biochem Pharmacol; 1980 Dec; 17():228-35. PubMed ID: 6894195
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR, Nakane M, Traylor L, Ruan X, Kroeger PE, Tian J.
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.